Search Results - "Azim, H.A."

Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Peccatori, F A, Azim, Jr, H A, Orecchia, R, Hoekstra, H J, Pavlidis, N, Kesic, V, Pentheroudakis, G

Get full text

Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies by Lambertini, M., Ceppi, M., Poggio, F., Peccatori, F.A., Azim, H.A., Ugolini, D., Pronzato, P., Loibl, S., Moore, H.C.F., Partridge, A.H., Bruzzi, P., Del Mastro, L.

“…The role of temporary ovarian suppression with luteinizing hormone-releasing hormone agonists (LHRHa) in the prevention of chemotherapy-induced premature…”
Get full text

SP-0181 BREAST CANCER IN YOUNG WOMEN: ADJUVANT THERAPY AND FERTILITY CONSIDERATIONS by Azim, H.A

Get full text

Long-term toxic effects of adjuvant chemotherapy in breast cancer by Azim, H.A., de Azambuja, E., Colozza, M., Bines, J., Piccart, M.J.

“…Breast cancer is the most common malignant tumor affecting women. Adjuvant systemic therapies have been shown to have a significant impact on reducing the risk…”
Get full text

IN24 Pregnancy after breast cancer by Azim, H.A

Get full text

Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement by Azim, H.A., Michiels, S., Zagouri, F., Delaloge, S., Filipits, M., Namer, M., Neven, P., Symmans, W.F., Thompson, A., André, F., Loi, S., Swanton, C.

“…We critically evaluated the available evidence on genomic tests in breast cancer to define their prognostic ability and likelihood to determine treatment…”
Get full text

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial by Huober, J, Fasching, P.A, Barsoum, M, Petruzelka, L, Wallwiener, D, Thomssen, C, Reimer, T, Paepke, S, Azim, H.A, Ragosch, V, Kubista, E, Baumgärtner, A.K, Beckmann, M.W, May, C, Nimmrich, I, Harbeck, N

“…Abstract The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor…”
Get full text

5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial by Gligorov, J., Pivot, X., Ataseven, B., De Laurentiis, M., Llombart, A., Jung, K.H., Manikhas, A., Azim, H.A., Alexandrou, A., Gupta, K., Herraez-Baranda, L., Tosti, N., Restuccia, E.

Get full text

Discrepancies between ESMO and NCCN breast cancer guidelines: An appraisal by Zagouri, Flora, Liakou, Paraskevi, Bartsch, Rupert, Peccatori, Fedro A, Tsigginou, Alexandra, Dimitrakakis, Constantine, Zografos, George C, Dimopoulos, Meletios-Athanassios, Azim, H.A

“…Abstract An ever growing number of medical organizations, societies, working groups and governmental agencies issue algorithms i.e. guidelines, of decision…”
Get full text

Understanding the biology of triple-negative breast cancer by Criscitiello, C., Azim, H.A., Schouten, P.C., Linn, S.C., Sotiriou, C.

Get full text

Treatment of breast cancer during pregnancy: Regimen selection, pregnancy monitoring and more by Azim, H.A, Del Mastro, L, Scarfone, G, Peccatori, F.A

“…Abstract Breast cancer is uncommonly diagnosed during pregnancy but when encountered, it poses several clinical conflicts. Managing patients with gestational…”
Get full text

1957 Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: A systematic review and meta-analysis of randomized studies by Lambertini, M, Ceppi, M, Poggio, F, Peccatori, F.A, Azim, H.A, Ugolini, D, Pronzato, P, Loibl, S, Moore, H.C.F, Partridge, A.H, Del Mastro, L

Get full text

1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses by Jung, K.H, Ataseven, B, Verrill, M, De Laurentiis, M, Azim, H.A, Pivot, X, Al-Sakaff, N, Lauer, S, Shing, M, Gligorov, J

Get full text

13P NON SQUAMOUS NSCLC IS MORE PLATINUM SENSITITVE THAN SQUAMOUS NSCLC by Fouad, E, Abdelrhman, O, Abdelmalek, R, Shahin, M, Azim, H.A

Get full text

21P CLINICOPATHOLOGICAL FEATURES OF ELDERLY PATIENTS WITH NSCLC; SINGLE INSTITUTIONAL EXPERIENCE FROM EGYPT by Shahin, M, Abdelrhman, O, Fouad, E, Abdelmalek, R, Azim, H.A

Get full text

P103 Subcutaneous trastuzumab plus chemotherapy for early breast cancer: interim safety from SafeHer by Gligorov, J, De Laurentiis, M, Verrill, M, Jung, K.H, Azim, H.A, Ataseven, B, Al-Sakaff, N, Heinzmann, D, Shing, M, Pivot, X

Get full text

Clinical utility of genomic tests in young women with breast cancer by Azim, H.A.

Get full text

161P SOLUBLE MESOTHELIN RELATED PROTEIN (SMRP) IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) by Azim, H.A, Gaafar, R, Abdelsalam, I, Khorshid, O, Elguindi, S, Elattar, I, Ashmawy, A

Get full text

144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy by Azim, H.A., Pöllinger, B.E.

Get full text

39 Actual or adjusted surface area: which should we use? by Abbas, N, Fattah, R.A, Malek, R, Azim, H.A

Get full text